Physician profile
Anna M Wells Sharp
NPI 1790019602
$1,111.01
in general payments reported to CMS, 2019-2025
19 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.72 · 2022: $145 · 2023: $210 · 2024: $284 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.74 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $223.83 | 2021-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $188.78 | 2024-2025 | Airsupra, Breztri |
| Abbvie INC. | $80.55 | 2021-2024 | |
| Novo Nordisk INC | $75.04 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $68.42 | 2022 | |
| Exact Sciences Corporation | $66.80 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $55.40 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $54.15 | 2023-2025 | Nuedexta, Rexulti |
| Alnylam Pharmaceuticals INC. | $44.38 | 2021-2025 | Onpattro |
| Currax Pharmaceuticals LLC | $40.81 | 2023 | Nexletol, Nexlizet, Contrave |
| Idorsia Pharmaceuticals US INC | $40.56 | 2023 | Quviviq |
| Lilly USA, LLC | $35.95 | 2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.56 | 2024 | Caplyta |
| Corcept Therapeutics | $30.25 | 2025 | Korlym |
| Avanir Pharmaceuticals, INC. | $18.00 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.23 | 2024 | Trelegy Ellipta |
| Amarin Pharma, INC. | $16.74 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.86 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Wells Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.